Phase 1 Study of OTS167 in Patients With Solid Tumors

Summary

The purpose of this study is to test the safety and tolerability of an investigational drug called OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this first-in-human study OTS167 will be administered to patients with solid tumors which have not responded to treatment.

Timeline

Start

2013-08-23

Primary completion

2016-04-11

Completion

2016-05-04

Drugs

Indications